These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17668559)

  • 1. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
    Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
    Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
    Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
    Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
    Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
    Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
    Hoetelmans RM; Mariën K; De Pauw M; Hill A; Peeters M; Sekar V; De Doncker P; Woodfall B; Lefebvre E
    Br J Clin Pharmacol; 2007 Nov; 64(5):655-61. PubMed ID: 17610528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Intervirology; 2010; 53(3):176-82. PubMed ID: 20197684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
    Sekar VJ; Lefebvre E; Guzman SS; Felicione E; De Pauw M; Vangeneugden T; Hoetelmans RM
    Antivir Ther; 2008; 13(4):563-9. PubMed ID: 18672535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
    Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
    Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
    Sekar VJ; Lefebvre E; De Marez T; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Drugs R D; 2007; 8(4):241-8. PubMed ID: 17596110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.